PYXS News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$150.1M

Volume

828.60K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Jun 28, 2024

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerBOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.GlobeNewswire Inc. · Jun 10, 2024

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.GlobeNewswire Inc. · May 30, 2024

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue EstimatesPyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 14, 2024

Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Zacks Investment Research · Apr 12, 2024

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement. Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences. Next Technology Holding Inc. (NASDAQ: NXTT) rose 57.4% to $6.42. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares climbed 39.3% to $5.45. Vanda Pharmaceuticals' Fanapt® received U.S. FDA approval for the acute treatment of Bipolar I Disorder. VivoPower International PLC (NASDAQ: VVPR) shares gained 39% to $8.20 after the company declared a capital management strategy including a stock buyback program of up to $5 million. Next.e.GO N.V. (NASDAQ: EGOX) gained 32.7% to $0.0345. XTI Aerospace, Inc. (NASDAQ: XTIA) rose 32.2% to $4.63. BestGrowthStocks.com issued comprehensive evaluation of XTI Aerospace, Inc. Brooge Energy Limited (NASDAQ: BROG) gained 28.8% to $3.0790. Addex Therapeutics Ltd (NASDAQ: ADXN) rose 24.6% to $16.21 after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix. Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH) gained 24.3% to $0.3981 after gaining 13% on Tuesday. LAMF Global Ventures Corp. I (NASDAQ: LGVC) gained 22.7% to $13.21. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd. Quhuo Limited (NASDAQ: QH) rose 21.7% to $0.6501 after reporting unaudited financial results for the second half and full year 2023. Destiny Tech100 Inc. (NYSE: DXYZ) gained 21.4% to $25.77. OneMedNet Corporation (NASDAQ: ONMD) gained 21.2% to $0.9600. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement ...Benzinga · Apr 3, 2024

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On WednesdayU.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE: SIG) rose sharply during Wednesday’s session after the company raised its FY25 guidance. The company and Leonard Green & Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. Signet increased its FY25 adjusted EPS outlook to $9.90 – $11.52 from $9.08 – $10.48 versus an estimate of $9.72. Signet Jewelers shares surged 9.2% to $103.80 on Wednesday. Here are some other big stocks recording gains in today’s session. Destiny Tech100 Inc. (NYSE: DXYZ) shares jumped 21.4% to $25.77. Ocugen, Inc. (NASDAQ: OCGN) shares gained 14.2% to $1.5750. HC Wainwright & Co. ...Benzinga · Apr 3, 2024

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired employee. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of March 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Mar 28, 2024

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The WaitPyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. See why PYXS stock is a Hold.Seeking Alpha · Mar 28, 2024

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsNon-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201GlobeNewswire Inc. · Mar 27, 2024

PYXSPyxis Oncology, Inc. Common Stock

PYXS

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any PYXS yet.

Related Tickers

Earnings

Volume

828.60K

Next Earnings

November 2nd